Background: The stability of ready-to-administer parenteral preparations is an important issue of drug safety. Profound knowledge about the physicochemical stability is necessary in order to determine the "beyond-usedates" of solutions in injection vials after first opening and ready-to-administer preparations in syringes. Object: The aim of this study was to determine the physicochemical stability of plerixafor solution marketed as Mozobil ® solution for injection 20 mg/mL (1.2 mL).
Introduction

Mozobil
® 20 mg/mL solution for injection containing plerixafor as active pharmaceutical ingredientis indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) [1] . Plerixafor (AMD3100) is a small bicyclamic molecule ( Figure 1 ) that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1), also known as CXCL12, to its cognate receptor CXCR4 [2] . Thereby plerixafor induces the mobilization of hematopoietic stem cells, which are characterized as CD34 + cells, from the bone marrow to the bloodstream [3] . In a phase III prospective randomized double-blind placebocontrolled trial of plerixafor plus G-CSF for autologous stem-cell mobilization in patients with non-Hodgkin's lymphoma was shown that plerixafor acts synergistic with G-CSF [4] . In another phase II clinical trial plerixafor in combination with G-CSF resulted in a significantly higher proportion of MM patients achieving the optimum CD34 + target range for transplantation in fewer apheresis days, compared with G-CSF alone [5] . Plerixafor is only used in patients expected to mobilize stem cells poorly, i. e. age over 60 and/or prior myelosuppressive chemotherapy and/or extensive prior chemotherapy and/or a peak circulating stem cell count of < 20 HSCs/µL [4] . Because the number of patients that need mobilization and collection of HSCs for transplantation is small, Mozobil ® was classified as an orphan drug in October 2004 [6] . Each single-use vial of Mozobil ® is filled to deliver 1.2 mL of 20 mg/mL plerixafor aqueous solution for injection containing 24 mg of plerixafor. The pH is adjusted in the range of 6.0-7.5 [1] . Plerixafor has eight basic amine functional groups, and is slightly soluble in water and saline, freely soluble in alcohols, glycol, and aqueous solutions of the pH < 10. Type I clear glass 2 mL vials are used as primary containers and closed with grey chlorobutyl rubber stoppers. According to the Mozobil ® label the product does not require any special storage conditions [1] . After opening the vial, the solution should be used immediately [1] . The content of each Mozobil ® vial is appropriate to treat a patient with 100 kg body weight (0.24 mg/kg/d used on 2-4 (and up to 7) consecutive days) [1] . For patients with a lower body weight, the remaining solution must be discarded, resulting in a significant waste of this expensive drug (5,800 € per 1 mL). According to the EPAR [6] stability of plerixafor active substance is given under a wide range of conditions (temperature, humidity, pH, light) and degradation is only observed under severe stress conditions. The results from photostability studies also show that plerixafor is not photosensitive and does not require special protection against light exposure [6] . Mozobil ® solution for injection is terminally sterilized in an autoclave. The specification of the finished product includes sterility and freedom from bacterial endotoxins [6] . The commercial packaging is stable for at least three years when stored at 25°C/60 % RH. No special precautions for storage are to be regarded [1] . In addition, the analysis and stability of repurposed plerixafor products over a period of six months at room temperature was published in abstract form [7] . Profound knowledge about the physicochemical stability is necessary in order to determine the in-use storage time of Mozobil ® solution for injection in vials after first opening and the beyond-use-date of ready-to-administer Mozobil ® containing preparations in 1 mL 2-piece plastic syringes. Decision-making is based on the physicochemical stability and concomitantly on the safe aseptic processing and is the responsibility of the pharmacist. Therefore, the purpose of this study is to determine the physicochemical stability of Mozobil ® solution for injection in the original vials after first opening and in readyto-administer syringes when stored under refrigeration (2-8°C) or at room temperature (25°C) both light protected over a period of 84 days. The storage conditions were chosen with an eye to clinical practice. Chemical stability of plerixafor was planned to be determined with a stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) assay which was previously published by M. Mathrusri Annapurna et al. [8] . Physicochemical stability was planned to be determined by visual inspection of clarity and colour as well as pH measurement. The cover was removed prior to the next sampling and the stopper was disinfected with alcohol before the aliquot was withdrawn.
Materials and methods
Preparation of test solutions
Six Mozobil ® ready-to-administer preparations were aseptically prepared by withdrawing 0.2 mL solution for injection from the same Mozobil ® vial in 1 mL 2-piece syringes (Injekt ® -F Tuberculin, 0.01 ml-1 ml, Luer Solo, lot-no.: 15G13C8, B. Braun Melsungen AG, DE) via cannulas. The barrel of the used syringe model is made of polypropylene (PP) and the plunger of polyethylene (PE). The syringe is free from latex, polyvinyl chloride (PVC) and silicone oil [9] . Three test syringes were stored under refrigeration (2-8°C) and additional three syringes were stored at room temperature (25°C), both light protected. Plerixafor concentrations were determined on days 0 and 84.
Sample preparation
Aliquots of the test solutions were twofold diluted in order to fit the calibration curve of the HPLC assay. In the first dilution step 25 µL aliquots of the test solutions were diluted with 975 µL mobile phase. Then 400 µL of the diluted solution were mixed with 600 µL mobile phase to achieve a concentration of 0.2 mg/mL plerixafor. The absorption of plerixafor was measured at a wave length of 215 nm. The identity of the plerixafor peak was confirmed by concentration dependent peak area and PDA-chromatogram.
Validation of the RP-HPLC assay
The method was validated following the ICH Q2 (R1) Guidelines [10] for stability studies. A typical HPLC chromatogram is shown in Figure 2 .
Suitability
Suitability of the HPLC method was proven by analyzing forced degraded samples of Mozobil ® plerixafor injection concentrate. The injection concentrate (20 mg/mL) was either acidified with 10 µL of hydrochloric acid 
Linearity
In order to study the linearity of the assay, standards (n = 7) were prepared by diluting Mozobil ® injection solution with mobile phase to achieve the following concentrations: 0.3 mg/mL, 0.24 mg/mL, 0.22 mg/mL, 0.2 mg/mL, 0.18 mg/mL, 0.16 mg/mL, 0.1 mg/mL. Aliquots of the calibration standards were injected in triplicate. The line of best fit was constructed by analyzing plots of peak area versus plerixafor concentrations.
Accuracy
Accuracy was evaluated with two different concentration levels (100 %: 0.2 mg/mL and 80 %: 0.16 mg/mL) and 10-fold injection.
Intra-day precision
The intra-day precision of the assay method was evaluated by carrying out 10 independent assays of plerixafor solution at two concentration levels (0.2 mg/mL and 0.16 mg/mL).
Inter-day precision
For inter-day precision at each concentration level (0.2 mg/mL and 0.16 mg/mL) a single injection of plerixafor solution was assayed daily on five consecutive days.
Determination of the physicochemical stability of plerixafor solution for injection pH values were measured in triplicate in the undiluted aliquots taken from the test solutions at the predetermined intervals using a pH 210 Microprocessor pHmeter (Hanna Instruments, Kehl am Rhein, DE) with an InLab Ultra-Micro pH-glasselectrode (Mettler Toledo Inlab Ultra-micro pH, Gießen, DE). The instrument was calibrated with Hamilton DuraCal buffer pH 4.01 ± 0.01 and pH 7.01 ± 0.01.
Whenever samples were taken the vials were visually checked for colour changes and particulate matter.
Results
Validation of the RP-HPLC assay Suitability
Under alkaline condition the peak of the degradation product (retention time 2.5 min) did not interfere with the plerixafor parent peak (retention time 7.5 min), see There were no changes induced by acidic degradation (Figure 4 ) and pure heating ( Figure 5 ).
These results confirm the suitability of the HPLC method. 
Linearity
The correlation coefficient of R 2 = 0.9994 proved linearity over the concentration range. The equation of calibration curve was y = 1.14e + 007x-1.02e + 005.
Accuracy
The mean recovery was 103.4 % ± 0.1 % (n = 10). The accuracy was 102.6 % ± 0.1 % for 0.2 mg/mL and 104.1 % ± 0.1 % for 0.16 mg/mL plerixafor solution.
Intra-day precision
The % RSD (Relative Standard Deviation) was 0.97 % at the concentration 0.2 mg/mL and 0.74 % at 0.16 mg/mL.
Inter-day precision
The % RSD was 1.23 % at the concentration 0.2 mg/mL and 4.73 % at 0.16 mg/mL.
Chemical stability of plerixafor solution for injection
In the present study two known HPLC-methods [7, 8] for evaluating the stability of Mozobil ® solution for injection were modified and validated. The overall run time amounted to 15 min, the flowrate to 1.0 mL/min, the injection volume to 10 µL. The mobile phase consisted of water, acetonitrile and trifluoroacetic acid (TFA). Samples were not filtered before measurement. Results of the degradation tests proved the suitability of the method. The validation parameters met the criteria of ICH Q2 (R1). Neither in samples taken from the re-punctured Mozobil ® glass vials nor taken from the aseptically prepared ready-to-administer syringes any plerixafor degradation products were detected in the HPLC chromatograms over the storage period of 84 days, independent of the temperature conditions. In addition no changes in the concentrations of plerixafor were registered. In vials and syringes plerixafor concentrations Tables 1 and 2 ).
Physicochemical stability of plerixafor solution for injection
No particulate matter and no colour changes were observed over the period of 84 days. The mean pH value varied from pH 6.71 at day 0 to pH 6.62 after three months in Mozobil ® glass vials (n = 18) ( Table 3 ).
The pH value remained unchanged in the ready-toadminister preparations in plastic syringes as primary containers (Table 4) .
Discussion
HPLC method
The used HPLC assay was adopted from published data [7, 8] and revalidated in order to achieve valid results. In the resulting chromatograms the sharp peak of plerixafor (retention time of about 8 min) was clearly separated from the peak of the sodium and/or chloride ion derived peak (retention time about 3 min). For that reason an overall runtime of 15 min was chosen. During the forced degradation experiments, the plerixafor parent peak and peaks of rarely observed degradation products were clearly separated. Also in previous degradation studies only minimal degradation was observed under most of the stress conditions applied [6] . According to the EPAR, increased levels of degradation have only been observed under severe stress conditions. No degradation products 
Note: Drug concentrations in samples taken at time zero were designated as 100 %. Table 3 : pH values of plerixafor injection solution in re-punctured vials stored under different storage conditions. pH values expressed as mean ± standard deviation of triplicate measurements of one test solution (n = 3).
Storage temperature Test solution pH values
or significant trends were observed under the conditions specified in the SmPC [1] .
Test solutions
Because of the body-weight adjusted dosage residual liquid will remain in the Mozobil ® vials. When the withdrawal of the injection solution is performed under controlled conditions the residual liquid can be stored in the original glass vials and re-used. In order to simulate this scenario six Mozobil ® vials were used for the stability tests. Re-puncturing of the vial stoppers was done more often than in daily practice thus representing an additional challenge. Storage of the test solutions at room temperature simulates worst conditions especially regarding microbiological stability. The preparation of ready-to-administer syringes was simulated by withdrawal of 0.2 mL aliquots into six 1 mL 2-piece plastic syringes free from silicon oil. Thereby only one single Mozobil ® vial had to be expended. A polyisoprene gasket is not necessary in 2-piece syringes and thereby the probability of leaching is reduced. The filling volume of the syringe is not expected to influence the degradation of plerixafor. On the contrary, the small filling volume (0.2 mL) represents a worse case condition because the disadvantageous ratio of volume and surface favours leaching. Plerixafor concentrations were determined only initially and at the end of the observation period because of the small available volumes.
Stability
No significant changes of plerixafor concentrations and pH values were found in the experimental tests of Mozobil ® solution for injection in vials after first opening and ready-to-administer preparations in plastic syringes.
Both products revealed to be physicochemically stable over a three-month period. On day 56, there was an outlier which is most probably caused by an imprecise dilution step (Table 1) . Marginal variations in plerixafor concentrations can be explained by the dilution steps during sample preparation and by the standard deviations of the HPLC method. Because of the known stability of plerixafor, degradation reactions are not to be expected in the Mozobil ® injection solution of neutral pH and storage at room temperature. However, contact with alkaline solutions should be avoided. As plerixafor is not photosensitive, light protection during storage is not mandatory, but light protected storage was chosen with an eye to daily practice. A temperature dependent difference in plerixafor stability (refrigerated or room temperature) gets most probably only obvious after longer storage periods. Disposable plastic syringes used as primary containers represent a source of leachables which can diffuse under certain solvent and storage conditions [11] . Compounds leached into the product can affect the stability of the product and potentially increase the toxicological risk for the patient [12, 13] . However, determination of leachables was not in the scope of our study. With regard to the aspect of leaching the results cannot be assigned to 3-piece syringes [9, 14] .
The present study has proven long-term physicochemical stability (84 days observation period) of readyto-administer Mozobil ® syringes and Mozobil ® vials after first opening. Besides the physicochemical stability, microbiological stability is a crucial factor in assigning extended expiration dates to aseptically prepared unpreserved aqueous injection products. Therefore, storage under growth-inhibiting temperature conditions, i. e. refrigeration is recommended. Moreover, only if handling takes place under strict aseptic conditions the prolonged use of these solutions can be recommended. Thereby material and therefore treatment expenses can be 
Conclusion
Plerixafor injection solution (Mozobil ® ) is stable in glass vials after first opening and in syringes for at least three months when stored light protected under refrigeration (2-8°C) or at room temperature (25°C). For microbiological reasons storage under refrigeration is recommended. The proven physicochemical stability of Mozobil ® allows cost-saving pharmacy-based centralized preparation of ready-to-administer syringes.
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